Cliff Asness's FULC Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 543,165 shares of Fulcrum Therapeutics, Inc. (FULC) worth $4.17 M, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in FULC, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 527,663 shares. Largest reduction occurred in Q4 2024, reducing 52,835 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Fulcrum Therapeutics (FULC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fulcrum Therapeutics (FULC) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +527,663 | Add 3403.84% | 543,165 | $7.67 |
| Q4 2025 | +15,502 | New Buy | 15,502 | $11.31 |
| Q3 2025 | -18,053 | Sold Out | 0 | $0.00 |
| Q2 2025 | +445 | Add 2.53% | 18,053 | $6.88 |
| Q1 2025 | -28,033 | Reduce 61.42% | 17,608 | $2.88 |
| Q4 2024 | -52,835 | Reduce 53.65% | 45,641 | $4.70 |
| Q3 2024 | +98,476 | New Buy | 98,476 | $3.57 |
| Q3 2022 | -13,966 | Sold Out | 0 | $0.00 |
| Q2 2022 | +13,966 | New Buy | 13,966 | $4.87 |
| Q1 2022 | -14,024 | Sold Out | 0 | $0.00 |
| Q4 2021 | +14,024 | New Buy | 14,024 | $17.68 |
Cliff Asness's Fulcrum Therapeutics Investment FAQs
Cliff Asness first purchased Fulcrum Therapeutics, Inc. (FULC) in Q4 2021, acquiring 14,024 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Fulcrum Therapeutics, Inc. (FULC) for 11 quarters since Q4 2021.
Cliff Asness's largest addition to Fulcrum Therapeutics, Inc. (FULC) was in Q1 2026, adding 543,165 shares worth $4.17 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 543,165 shares of Fulcrum Therapeutics, Inc. (FULC), valued at approximately $4.17 M.
As of the Q1 2026 filing, Fulcrum Therapeutics, Inc. (FULC) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Fulcrum Therapeutics, Inc. (FULC) was 543,165 shares, as reported at the end of Q1 2026.